Premium
THE EFFICACY OF A SINGLE DOSE OF INTRAVENOUS FERRIC CARBOXYMALTOSE (FERINJECT ® ) ON ANAEMIA IN A PRE‐DIALYSIS POPULATION OF CHRONIC KIDNEY DISEASE PATIENTS
Author(s) -
Tagboto Senyo,
Cropper Liz,
Turner June,
PughClarke Karen
Publication year - 2009
Publication title -
journal of renal care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.381
H-Index - 27
eISSN - 1755-6686
pISSN - 1755-6678
DOI - 10.1111/j.1755-6686.2009.00075.x
Subject(s) - medicine , kidney disease , dialysis , iron deficiency , population , drug , anemia , pharmacology , environmental health
SUMMARY Anaemia due to chronic kidney disease (CKD) is common and may be managed with erythropoiesis stimulating agents and/or iron preparations. Iron preparations may be administered orally, intravenously or by intramuscular injection. Oral preparations pose a significant tablet burden on patients who are often taking multiple medications and may have undesirable gastrointestinal side effects. The existing intravenous preparation Venofer ® requires multiple doses of drug (typically 100–200 mg) at multiple clinic visits. The preparation Cosmofer ® may be given as a single dose, but this requires four to six hours to administer. For these reasons, their use in pre‐dialysis patients remains limited in practice. The new intravenous iron preparation Ferric Carboxymaltose (Ferinject ® ) may be given as a single dose of up to 1000 mg (but not exceeding 15 mg/kg/week) as an infusion over 6–15 minutes. This offers a significant advance in the management of these patients. We describe our initial experience with using this drug in a non‐dialysis patient population with chronic kidney disease.